← boardnext 2028-11
NGNE
Neurogene Inc.distress 3/10 · well-funded / low risk$35.84-1%today-16% from 52w high
Lead: Rett syndrome
Revenue
pre-revenue
Liquidity
$243M
Runway
3.0 yrs
Shares 1y
+11%
Price & events
+88.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.8%
1D
-1.8%
1W
+16.1%
1M
+33.0%
3M
+95.7%
6M
+55.2%
1Y
-16.7%
2Y
-77.6%
5Y
-87.3%
All
Overview
- Market Cap
- $566.26M
- Volume
- 4.01K
- 52 Week Range
- $16.37 – $42.84
- Total Shares
- 15.80M
- Float Shares
- 8.83M
- Short %
- 26.44%
- % Held by Insiders
- 7.07%
- % Held by Institutions
- 88.49%
- RVOL
- 0.01x
- Beta
- 1.96
Pipeline stages · 1 programs
NGN-401
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
Catalyst news & presentations · 4
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
- June 29, 2026readoutPhase 1/2NGN-401 · Positive updated clinical data from Phase 1/2 trial.SEC 8-K
- fourth quarter of 2025trial initiationsecondaryNGN-401 · Dose first participant in registrational trialSEC 8-K
- November 12, 2025readoutPhase 1/2NGN-401 · Positive updated interim clinical data in pediatric cohort (ages 4-10)SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $82 (+128% upside) · 7 analysts
- 2026-06-09HC Wainwright & Co.Buy
- 2026-04-06Canaccord GenuityBuy
- 2026-02-27Canaccord GenuityBuy
- 2026-01-26LifeSci CapitalOutperform
- 2026-01-13HC Wainwright & Co.Buy
- 2025-11-13HC Wainwright & Co.Buy
Competitors — Rett syndrome
- TSHATaysha Gene Therapies, Inc.$1.6B · D2
Recent news
- 2026-07-21Neurogene Completes $143.7 Million Public Offering of Shares and Pre-Funded Warrants - Global Legal Chronicle
- 2026-07-17Neurogene prices $125M equity offering - MSN
- 2026-07-17Neurogene prices $125M equity offering - MSN
- 2026-07-09Neurogene Surges To A New 52-Week High: Will NGN-401 Reshape The Rett Syndrome Market? - RTTNews
- 2026-07-07Neurogene (NGNE) CFO sells 4,800 shares and retains 84,040 including RSUs - Stock Titan
- 2026-07-07Neurogene president & CFO Cvijic sells $173,375 in stock - Investing.com
- 2026-07-06Neurogene lures 6 new hires with stock options tied to July 6 close - Stock Titan
- 2026-07-02Neurogene president and CFO Cvijic sells $166,586 of company stock - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.